Metformin and Sulfonylureas in Relation to Cancer Risk in Type II Diabetes Patients: A Meta-analysis using primary data of published studies

Metabolism: Clinical and Experimental

Volumn 62, Issue 7, 2013, Pages 922-934

  Thakkar, Bindiya ^a,b   Aronis, Konstantinos N ^a,b   Vamvini, Maria T ^a   Shields, Kelsey ^a   Mantzoros, Christos S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti diabetic medications; Cancer incidence; Diabetes mellitus

Indexed keywords

METFORMIN; SULFONYLUREA;

CANCER CELL CULTURE; CANCER INCIDENCE; CANCER INHIBITION; CANCER MORTALITY; CANCER RISK; CARCINOGENESIS; CELL CYCLE ARREST; CELL PROLIFERATION; CLINICAL PRACTICE; COLONY FORMATION; HUMAN; HYPERINSULINEMIA; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOGENS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NEOPLASMS; RISK; SULFONYLUREA COMPOUNDS;

EID: 84879552899     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2013.01.014     Document Type: Review

References (65)

1. WHO, 2011. The top 10 causes of death, World Health Organization; accessed 30 July 2012 http://www.who.int/mediacentre/factsheets/fs310/en/index. html.
2. American Cancer Society, 2012. Cancer facts and figures [cited 2012 30 July]; available from: http://www.cancer.org/acs/groups/content/ @epidemiologysurveilance/documents/document/acspc-031941.pdf.
3. ADA Economic costs of diabetes in the U.S. in 2007 Diabetes Care 31 3 2008 596 615
4. P. Vigneri Diabetes and cancer Endocr Relat Cancer 16 4 2009 1103 1123
5. M. Pollak Insulin and insulin-like growth factor signalling in neoplasia Nat Rev Cancer 8 12 2008 915 928
6. M. Monami Sulphonylureas and cancer: a case-control study Acta Diabetol 46 4 2009 279 284
7. Y.X. Yang, S. Hennessy, and J.D. Lewis Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients Gastroenterology 127 4 2004 1044 1050
8. S.L. Bowker Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: response to Farooki and Schneider Diabetes Care 29 8 2006 1990 1991
9. M. Monami Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality Diabetes Metab Res Rev 23 6 2007 479 484
10. C.J. Currie, C.D. Poole, and E.A. Gale The influence of glucose-lowering therapies on cancer risk in type 2 diabetes Diabetologia 52 9 2009 1766 1777
11. J.M. Evans Metformin and reduced risk of cancer in diabetic patients BMJ 330 7503 2005 1304 1305
12. G. Libby New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes Diabetes Care 32 9 2009 1620 1625
13. G.W. Landman Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16 Diabetes Care 33 2 2010 322 326
14. A. Liberati The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration J Clin Epidemiol 62 10 2009 e1 e34
15. D.F. Stroup Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group JAMA 283 15 2000 2008 2012
16. Team, R.D.C., R: a language and environment for statistical computing. R.F.f.S. Computing, Editor 2011.
17. Schwarzer G. meta: meta-analysis with R2010.
18. P.J. Easterbrook Publication bias in clinical research Lancet 337 8746 1991 867 872
19. V. Donadon Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin World J Gastroenterol 14 37 2008 5695 5700
20. V. Donadon Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease World J Gastroenterol 15 20 2009 2506 2511
21. V. Donadon, M. Balbi, and G. Zanette Hyperinsulinemia and risk for hepatocellular carcinoma in patients with chronic liver diseases and type 2 diabetes mellitus Expert Rev Gastroenterol Hepatol 3 5 2009 465 467
22. V. Donadon Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma World J Gastroenterol 16 24 2010 3025 3032
23. X. Yang Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry Diabetes Care 34 2 2011 375 380
24. N.E. Morden Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients Diabetes Care 34 9 2011 1965 1971
25. T.J. Murtola Antidiabetic medication and prostate cancer risk: a population-based case-control study Am J Epidemiol 168 8 2008 925 931
26. A. Hitron The influence of antidiabetic medications on the development and progression of prostate cancer Cancer Epidemiol 36 4 2012 e243 e250
27. S.W. Lai Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study Am J Gastroenterol 107 1 2012 46 52
28. T.P. van Staa Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data Diabetologia 55 3 2012 654 665
29. P.D. Home Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials Diabetologia 53 9 2010 1838 1845
30. R. Ruiter Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study Diabetes Care 35 1 2012 119 124
31. D.M. Baur Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort Metabolism 60 10 2011 1363 1371
32. H.W. Hense Cancer incidence in type 2 diabetes patients - first results from a feasibility study of the D2C cohort Diabetol Metab Syndr 3 1 2011 15
33. M.S. Lee Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals BMC Cancer 11 2011 20
34. X. Yang Use of sulphonylurea and cancer in type 2 diabetes - the Hong Kong Diabetes Registry Diabetes Res Clin Pract 90 3 2010 343 351
35. C.H. Tseng Diabetes and risk of prostate cancer: a study using the National Health Insurance Diabetes Care 34 3 2011 616 621
36. C.H. Tseng Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan Diabetologia 54 8 2011 2009 2015
37. A.E. Buchs, and B.G. Silverman Incidence of malignancies in patients with diabetes mellitus and correlation with treatment modalities in a large Israeli health maintenance organization: a historical cohort study Metabolism 60 10 2011 1379 1385
38. M. Bodmer Long-term metformin use is associated with decreased risk of breast cancer Diabetes Care 33 6 2010 1304 1308
39. M. Bodmer Use of metformin and the risk of ovarian cancer: a case-control analysis Gynecol Oncol 123 2 2011 200 204
40. T. Kawaguchi Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection Liver Int 30 3 2010 479 486
41. M.M. Hassan Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma Cancer 116 8 2010 1938 1946
42. V. Donadon Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease Liver Int 30 5 2010 750 758
43. M. Monami Metformin and cancer occurrence in insulin-treated type 2 diabetic patients Diabetes Care 34 1 2011 129 131
44. D. Li Antidiabetic therapies affect risk of pancreatic cancer Gastroenterology 137 2 2009 482 488
45. J.L. Wright, and J.L. Stanford Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study Cancer Causes Control 20 9 2009 1617 1622
46. J.L. Bosco Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark Cancer Epidemiol Biomarkers Prev 20 1 2011 101 111
47. L. Azoulay Metformin and the incidence of prostate cancer in patients with type 2 diabetes Cancer Epidemiol Biomarkers Prev 20 2 2011 337 344
48. M. Bodmer Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis Am J Gastroenterol 107 4 2012 620 626
49. M. Bodmer Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis Cancer Epidemiol Biomarkers Prev 21 2 2012 280 286
50. A. Decensi Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis Cancer Prev Res 3 11 2010 1451 1461
51. H. Noto Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis PLoS One 7 3 2012 e33411
52. D. Soranna Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis Oncologist 17 6 2012 813 822
53. R.J. Shaw The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin Science 310 5754 2005 1642 1646
54. I.N. Alimova Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro Cell Cycle 8 6 2009 909 915
55. M.J. Gunter Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women J Natl Cancer Inst 101 1 2009 48 60
56. J. Ma A prospective study of plasma C-peptide and colorectal cancer risk in men J Natl Cancer Inst 96 7 2004 546 553
57. S.E. Dunn Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice Cancer Res 57 21 1997 4667 4672
58. Y. Wu Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis Cancer Res 62 4 2002 1030 1035
59. J.A. Johnson, and S.L. Bowker Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials Diabetologia 54 1 2011 25 31
60. I.F. Tannock, and I. Kopelyan Influence of glucose concentration on growth and formation of necrosis in spheroids derived from a human bladder cancer cell line Cancer Res 46 6 1986 3105 3110
61. A. Sliwinska, J. Blasiak, and J. Drzewoski Effect of gliclazide on DNA damage in human peripheral blood lymphocytes and insulinoma mouse cells Chem Biol Interact 162 3 2006 259 267
62. J.A. Johnson Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence Diabetologia 55 6 2012 1607 1618
63. S. Suissa, and L. Azoulay Metformin and the risk of cancer: time-related biases in observational studies Diabetes Care 35 12 2012 2665 2673
64. WHO. 2011. Facts and figures about diabetes; accessed 30 July 2012; http://www.who.int/features/factfiles/diabetes/en/index.html. Available from: http://www.who.int/features/factfiles/diabetes/en/index.html.
65. A. Jemal Global cancer statistics CA Cancer J Clin 61 2 2011 69 90 Diseases Diseases Diseases